Is venture philanthropy still a thing? TransCode Therapeutics has something novel for breast cancer. TransCode’s lead therapeutic candidate, TTX-MC138, is a targeted therapy designed to treat cancer patients with metastatic cancer- regardless of type. This could really help a lot of

#AI continues moving into #mbc arena Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications menarini.com/en-us/news/new…

anything for Er+ Her2- ⁦City of Hope⁩ ??? 4 Breast Cancer Treatment Breakthroughs to Look for in 2024 cityofhope.org/4-breast-cance…

This is.. something. So how to weaponize #AI against #mbc? Recursion would you please pinpoint 1. a drug to trigger anticipatory UPR in cancer cells.. 2. A molecule to break up the duo MTDH-SND1 3. an MYC inhibitor 4. confirm the best molecule to target miRNA-10b

Praying this is another line 📸 Look at this post on Facebook petermac.org/about-us/news-…

32 out of 42 patients treated since 2022 remain alive suggesting consistently strong survival benefit. bit.ly/3t51f8J $BCTX $BCTXW

Update !! #ERX315 for #mbc is looking to go to trial in Australia in May. ERX-315 targets BC mutations “inducing significant endoplasmic reticulum stress.” Ie blows #MBC up! ERX-315 does not induce cell death in normal cells and is non-toxic in animal models. Here is an

Hollings researchers find Boswellia, an extract of frankincense, shows anti-cancer activity in patients with breast cancer | MUSC Hollings Cancer Center hollingscancercenter.musc.edu/news/archive/2…

no mention of Er+ Her2- #mbc in Imugene | Cancer Immunotherapies CEO Chong’s presentation at Morgan Healthcare Conference. I’m pretty sure they have Er+ #mbc patients in the ongoing cf-33 trial (oncarlytic virus). I assume Er+ will be in the upcoming OnCARlytics trial (cf-33 w/ cd19). Anyone

“The City of Hope team has identified human ILC2 cells as a new member of the cell family capable of directly killing all types of cancers, including solid tumors.” Please fast track ILC2 for metastatic breast cancer patients. #WorldCancerDay #MBC #bcsm cityofhope.org/city-hope-rese…

Your gut feeling on antibiotics, cancer science.org/content/articl…

FDA Grants Fast Track Status to Vepdegestrant for ER+/HER2– Metastatic Breast Cancer onclive.com/view/fda-grant…

you need an expert on that … Erika Hamilton, MD from the one study: Patients had received a median of 4 prior therapies across all lines… Most patients previously received a CDK/4 inhibitor (87%), fulvestrant (80%), and chemotherapy (76%).

BriaCell reports disease control rate of 61% in evaluable Phase 2 advanced #breastcancer patients treated with BriaCell’s Bria-IMT™ regimen – the same formulation being used in BriaCell’s pivotal Phase 3 study. Find details: bit.ly/3usHx7B $BCTX $BCTXW

cool but no Er+ Her2- #MBC in trial?

MET-X: “Metasasis is the underlying cause of most solid tumor cancer deaths.MET-X will emphasize detecting & ultimately curing metastasis. Uncovering the fundamental principles of metastasis will form the bedrock of curative therapies” #MBC #bcsm NIH Vice President Kamala Harris fredhutch.org/en/research/in…

Phase III study everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve PFS” #MBC #bcsm